BIP
GALT icon

Brandes Investment Partners’s Galectin Therapeutics GALT Stock Holding History

Brandes Investment Partners’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-28,500
Closed -$70K – 142
2017
Q2 		$70K Hold
28,500
– – ﹤0.01% 175
2017
Q1 		$66K Buy
+28,500
New +$43K ﹤0.01% 187

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Brandes Investment Partners's GALT Position: Q3 2017 in Review

Brandes Investment Partners sold out of Galectin Therapeutics (GALT) in Q3 2017, closing a stake of 28,500 shares — an estimated $70K sold.

Brandes Investment Partners first reported a position in GALT in Q1 2017 and held it in 2 quarters. The position peaked at $70K in Q2 2017. 49 funds tracked by Wall St. Rank hold GALT as of Q3 2017.

  • Brandes Investment Partners reported no remaining Galectin Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Brandes Investment Partners sold 28,500 Galectin Therapeutics shares in Q3 2017, an estimated $70K.
  • Brandes Investment Partners first reported a position in Galectin Therapeutics in Q1 2017 and held it in 2 quarters.
  • Brandes Investment Partners's Galectin Therapeutics position peaked at $70K in Q2 2017.
  • 49 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2017.

Based on Brandes Investment Partners's 13F filing for Q3 2017, filed 13 Nov 2017.